Omega Therapeutics Q4 2022 Earnings Report $0.90 +0.04 (+5.12%) (As of 12:30 PM ET) Earnings HistoryForecast Omega Therapeutics EPS ResultsActual EPS-$0.64Consensus EPS -$0.62Beat/MissMissed by -$0.02One Year Ago EPSN/AOmega Therapeutics Revenue ResultsActual Revenue$0.74 millionExpected Revenue$0.65 millionBeat/MissBeat by +$90.00 thousandYoY Revenue GrowthN/AOmega Therapeutics Announcement DetailsQuarterQ4 2022Date3/1/2023TimeN/AConference Call ResourcesPress ReleaseOMGA Earnings HistoryPowered by Healthcare Takes A Big Step Forward With The Help of A.I. (Ad)To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.Click here to learn more about the booming eHealth industry - and see which microcap will be at the Omega Therapeutics Earnings HeadlinesOmega Therapeutics Elects Ravi Mehrotra, Ph.D. as Director, Sees Resignations from Board MembersDecember 9, 2024 | americanbankingnews.comOmega Therapeutics Appoints New Director Ravi MehrotraDecember 6, 2024 | tipranks.comHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.December 18, 2024 | Wall Street Star (Ad)Omega Therapeutics Reports Third Quarter 2024 ResultsNovember 19, 2024 | markets.businessinsider.comOmega Therapeutics price target lowered to $4 from $9 at Piper SandlerNovember 16, 2024 | markets.businessinsider.comPiper Sandler Remains a Buy on Omega Therapeutics (OMGA)November 16, 2024 | markets.businessinsider.comSee More Omega Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Omega Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Omega Therapeutics and other key companies, straight to your email. Email Address About Omega TherapeuticsOmega Therapeutics (NASDAQ:OMGA) operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.View Omega Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
